RxDoctor Payments Data

Michael Moriarty

Urology · Cedar Rapids, IANPI 1487072112

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (42.2%), education and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Intuitive Surgical at 59.6% of the total. 2025 is the largest year on record at $4,446, more than ten times the $123 reported in 2019.

$8,359in general payments, 2019–2025

Across 70 payments — averaging $119.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Valencia Technologies Corporation$1K
  • Neotract Inc.$1K
  • Boston Scientific$266
  • Teleflex LLC$161
  • 180 Medical, Inc.$128
  • plus $583 from 15 others

What the payments were for

  • Travel & lodging$3,53042%
  • Food & beverage$1,81022%
  • Education$3,01936%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,359 in reported general payments places this provider in the 85th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$409,362
Medicare patients
642
Services billed
16,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron134$78,359
GemtesaVibegron18$12,827
Tamsulosin Hcl779$6,714
Finasteride796$6,223
Trimethoprim41$4,163
Testosterone33$3,242
Oxybutynin Chloride ErOxybutynin Chloride222$3,152
Potassium Citrate ErPotassium Citrate48$2,653
Solifenacin Succinate85$2,153
Estradiol20$1,615
Tolterodine Tartrate ErTolterodine Tartrate31$1,457
Cephalexin130$1,223
Alfuzosin Hcl ErAlfuzosin Hcl57$724
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim76$590
Testosterone Cypionate17$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$41$78,359134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 114 urology providers in Iowa.

Other urology in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →